We found a match
Your institution may have rights to this item. Sign in to continue.
- Title
Phase I study of paclitaxel plus irinotecan combination therapy for patients with refractory and advanced gastric cancer.
- Authors
KOBAYASHI, T.; SAKAGAMI, T.; KOIZUKA, H.; YAMAMOTO, N.; SASAKI, T.; MAEDA, Y.; OMURO, Y.; OKAMOTO, R.; MIKOSHIBA, M.; SASAKI, E.; MATSUMOTO, T.; MIWA, H.
- Abstract
Background No adequate second-line chemotherapy regimen for advanced gastric cancer is available. Aims To determine the safety and optimal dose of paclitaxel/irinotecan as a second-line chemotherapy for patients with advanced and recurrent gastric cancer. Patients and methods Sixteen patients with refractory and advanced measurable gastric cancer who were resistant to 5-FU plus cis-diamminedichloroplatinum (CDDP) therapy (FP) were enrolled. Paclitaxel/irinotecan was given intravenously on days 1, 8, and 15 in repeated 4-week cycles. Paclitaxel/irinotecan doses were escalated in a stepwise fashion as follows: 50/40 mg/m2, 50/50 mg/m2, 50/60 mg/m2, 60/60 mg/m2, 60/70 mg/m2 in levels I, II, III, IV and V, respectively. Results Because of one patient with Grade 3 febrile neutropenia at level I, three more patients were enrolled in level I. Doses were consequently escalated, and in level IV, Grade 3 febrile neutropenia occurred in one patient. Since an additional patient in level IV had grade 4 neutropenia, Level IV was judged as the maximum tolerated dose (MTD). The recommended dose and schedule for phase II study is paclitaxel 50 mg/m2 and irinotecan 60 mg/m2 on days 1, 8, and 15 every 4 weeks. Partial response was observed in 4 of 16 patients. Conclusion Paclitaxel/irinotecan combination regimen at the level III dosage was safe and well tolerated.
- Subjects
PACLITAXEL; ANTINEOPLASTIC agents; CANCER patients; GASTRIC diseases; DRUG therapy; CISPLATIN; FEBRILE neutropenia
- Publication
Alimentary Pharmacology & Therapeutics, 2006, p266
- ISSN
0269-2813
- Publication type
Article
- DOI
10.1111/j.1365-2036.2006.00055.x